PDS Biotechnology (NASDAQ:PDSB) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report published on Wednesday morning, Benzinga reports. The firm currently has a $21.00 price objective on the stock.

Several other research firms also recently weighed in on PDSB. B. Riley reduced their price objective on shares of PDS Biotechnology from $11.00 to $9.00 and set a buy rating for the company in a report on Wednesday, June 12th. Alliance Global Partners raised shares of PDS Biotechnology to a strong-buy rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, PDS Biotechnology presently has a consensus rating of Moderate Buy and an average price target of $14.25.

PDS Biotechnology Stock Down 6.3 %

PDS Biotechnology stock opened at $3.71 on Wednesday. The firm has a market capitalization of $136.08 million, a P/E ratio of -2.73 and a beta of 1.90. The company has a 50-day simple moving average of $3.24 and a 200-day simple moving average of $3.34. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company posted ($0.37) earnings per share. As a group, equities analysts expect that PDS Biotechnology will post -1.3 earnings per share for the current year.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new stake in PDS Biotechnology in the 2nd quarter valued at about $146,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in PDS Biotechnology during the 2nd quarter worth about $115,000. Squarepoint Ops LLC acquired a new stake in PDS Biotechnology during the 2nd quarter worth about $120,000. Blair William & Co. IL raised its holdings in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after buying an additional 81,743 shares during the period. Finally, Ground Swell Capital LLC acquired a new stake in PDS Biotechnology during the 2nd quarter worth about $67,000. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.